A Phase 3 interventional study of Celecoxib and Celecoxib in Pharyngitis, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 18 Years. Per ClinicalTrials.gov, last updated 2021-03-03.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies in Pharyngitis with a site in United States — 4 open to participants now, 5 under way, none of them phase 3. Pharyngitis · United States.
Among the 41 studies in Pharyngitis with a site in United States, this one is the 15th largest by enrollment of the 35 interventional ones that give a count, is one of 3 that started in 2006, is one of 18 in phase 3, and was the 7th registered.
227 studies on the registry are indexed under Pharyngitis; 36 are open to participants now.
Browse Pharyngitis studies →4 of the 41 studies in Pharyngitis with a site in United States are open now. Recruiting first, the newest first:
SalivIQ Diagnostics, Inc. · Sites in United States
Ages 3+
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 1 mo–99 yrs
University of Pittsburgh · Sites in United States
Ages 6 mo–24 mo
The University of Texas Health Science Center, Houston · Sites in United States
Ages 3–18
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 19 Pharyngitis studies recruiting now, 5 (26%) set no upper age limit and 10 (53%) stop at 75 or younger; 8 take children under 18; 5 take healthy volunteers.
This study: 18 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 3 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 269 is above the median of 144 across 189 interventional studies indexed under Pharyngitis.
Median enrollment 204 across the 35 interventional studies, 587 across the 6 observational. Of the 33 that completed or were terminated, 13 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 41 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
Viatris Inc. has 1 study filed under Pharyngitis — fewer than ten, so there is no comparison to draw.
1 of the studies in Pharyngitis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07891728SalivIQ Diagnostics, Inc.A Multicenter Evaluation of SalivIQ™ Strep A for Detecting Group A Streptococcus From Saliva and Throat Swabs in Patients With Acute Pharyngitis | 2027-01-31 |
Add it to your calendar (.ics) → With an account.
Among the 41 studies in Pharyngitis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
We are proposing a study in which we utilize and augment the sore throat pain model to assess the analgesic effectiveness of celecoxib compared to placebo in patients with painful pharyngitis under randomized, double-blind, placebo-controlled conditions.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Celecoxib
Drug: Celecoxib
Drug: celecoxib
Drug: placebo
dose 1 celecoxib 50 mg followed 6-12 hours later by dose 2 celecoxib 50 mg
dose 1 celecoxib 100 mg followed 6-12 hours later by dose 2 placebo
dose 1 celecoxib 100 mg followed 6-12 hours later by dose 2 celecoxib 50 mg
dose 1 placebo followed 6-12 hours later by dose 2 placebo
Sum of Sore Throat Pain Intensity Difference (SPID2) on Swallowing at 2 Hours Post-First Dose
Based on the Pain Intensity scores measured on a Visual Analogue Scale (PI-VAS: 0mm=no pain,100mm=worst possible pain), assessed by the subjects, the SPID2 is the area under the curve (AUC) over the 2-hour period post-first dose of the Pain Intensity Difference (PID) scores using the trapezoidal rule.
Time frame: 2 hours Post-First Dose
Sore Throat Pain Intensity Difference (PID) Within 6 Hours Post-First Dose
Pain intensity (PI) on Swallowing as Measured by PI-VAS scale: 0mm=no pain, 100mm=worst possible pain. Sore throat PID score was obtained by subtracting the PI at each time point from the Baseline PI score. Increase in scores indicated a lessening of subjects' pain compared to baseline scores; higher scores indicated a greater reduction in pain.
Time frame: Within First 6 hours Post-First Dose
Sore Throat Pain Intensity Difference (PID) From 7 to 24 Hours Post-First Dose
Pain intensity (PI) on Swallowing as Measured by PI-VAS scale: 0mm=no pain, 100mm=worst possible pain. PID score was obtained by subtracting the PI at each time point from the Baseline PI score. An increase in scores indicated a lessening of subjects' pain as compared to Baseline scores, thus, higher scores indicated a greater reduction in pain.
Time frame: 7 to 24 hours
Sum of Sore Throat Pain Intensity Difference (SPID) Within 6 Hours Post-First Dose
The sum of pain intensity differences (SPID) was calculated as the AUC of the Pain Intensity Difference (PID) scores. The PID \[based on PI-VAS scale: 0mm=no pain, 100mm=worst possible pain\] was calculated as the difference between the pain intensity at the time and at baseline.
Time frame: up to 6 hours
Sum of Sore Throat Pain Intensity Difference (SPID) From 7 to 24 Hours Post-First Dose
The sum of pain intensity differences (SPID) was calculated as the AUC of the Pain Intensity Difference (PID) scores. The PID \[based on PI-VAS scale: 0mm=no pain, 100mm=worst possible pain\] was calculated as the difference between the pain intensity at the time and at baseline.
Time frame: 7 to 24 hours
Sore Throat Relief Rating Scale (STRRS) Within 6 Hours Post-First Dose
STRRS score (scale: 0 no relief to 6 complete relief); a higher pain score indicated a greater reduction in pain.
Time frame: within the first 6 hours
Sore Throat Relief Rating Scale (STRRS) From 7 to 24 Hours Post-First Dose
STRRS score (scale: 0 no relief to 6 complete relief); a higher score indicated a greater reduction in pain.
Time frame: 7 to 24 hours
Sore Throat Relief Rating Scale (STRRS) - 'Moderate Relief' at 6 Hours Post-First Dose
Subjects Achieving at Least 'Moderate Relief' as Measured by STRRS (range: 0=no relief to 6=complete relief); Moderate relief is defined as STRRS = 3).
Time frame: at 6 hours
Sore Throat Relief Rating Scale (STRRS) - 'Moderate Relief' at 12 Hours Post-First Dose
Subjects Achieving at Least 'Moderate Relief' as Measured by STRRS (range: 0=no relief to 6=complete relief); Moderate relief is defined as STRRS = 3).
Time frame: 12 hours
Time to Perceptible Pain Relief
Defined as time (measured by stopwatch) when subject began to feel any pain relieving effect from the drug
Time frame: Within 2 Hours Post-First Dose
Time to Meaningful Pain Relief
The time (measured by stopwatch) when the subject felt their pain relief was meaningful to them was not estimable thus the number of subjects experiencing meaningful pain relief within 2 hours of first dose is reported
Time frame: Within 2 Hours Post-First Dose
Time to Onset of Analgesia
Equal to time of perceptible pain relief when both perceptible pain relief and meaningful pain relief were experienced- the median time was not estimable thus the number of subjects with onset of analgesia within 2 hours of first dose is reported
Time frame: Within 2 Hours Post-First Dose
Patient's Global Evaluation of Study Medication at 6 Hours Post-First Dose
Subject assessment of overall impression of study drug on 4 point scale from 1 (poor) to 4 (excellent)
Time frame: 6 Hours Post-First Dose
Patient's Global Evaluation of Study Medication at 12 and 24 Hours Post-First Dose
Subject assessment of overall impression of study drug on 4 point scale from 1 (poor) to 4 (excellent)
Time frame: 12 and 24 hours Post-First Dose
Throat Soreness Scale (TSS) Difference Within 6 Hours Post-First Dose
The Pain Intensity Difference (PID) based on TSS (scale: 0=not sore to 10=very sore) was calculated as the difference between the pain intensity at the time and at baseline.
Time frame: Within first 6 hours post-first dose
Throat Soreness Scale (TSS) Difference From 7 to 24 Hours Post-First Dose
The Pain Intensity Difference (PID) based on TSS (scale: 0=not sore to 10=very sore) was calculated as the difference between the pain intensity at the time and at baseline.
Time frame: 7 to 24 hours post-first dose
Sore Throat Pain Intensity Difference (SPID2) as Measured by Throat Soreness Scale (TSS) at 2 Hours Post-First Dose
SPID2 was calculated as the AUC of the Pain Intensity Difference (PID) scores. The Sore Throat PID was calculated as the difference between the pain intensity (TSS scale: 0=not sore to 10=very sore) at 2 hours post dose and at baseline.
Time frame: 2 hour period Post-First Dose
Sum of Throat Soreness Difference as Measured by Throat Soreness Scale (TSS) Within 6 Hours Post-First Dose
The sum of sore throat pain intensity differences (SPID) was calculated as the AUC of the Pain Intensity Difference (PID) scores. The Sore Throat PID was calculated as the difference between the pain intensity (TSS range: 0=not sore to 10=very sore) at the time and at baseline.
Time frame: Within 6 hours Post-First Dose
Sum of Throat Soreness Difference as Measured by Throat Soreness Scale (TSS) From 7 to 24 Hours Post-First Dose
The sum of sore throat pain intensity differences (SPID) was calculated as the AUC of the Pain Intensity Difference (PID) scores. The Sore Throat PID was calculated as the difference between the pain intensity (TSS range: 0=not sore to 10=very sore) at the time and at baseline.
Time frame: 7 to 24 hours Post-First Dose
Difficulty Swallowing Difference as Measured by Difficulty Swallowing Scale (DSS) Within 6 Hours Post-First Dose
The Difficulty Swallowing Pain Intensity Difference (PID) was calculated as the difference between the pain intensity (DSS range: 0mm=not difficult, 100mm=very difficult) at the time and at baseline.
Time frame: Within 6 hours Post-First Dose
Difficulty Swallowing Difference as Measured by Difficulty Swallowing Scale (DSS) From 7 to 24 Hours Post-First Dose
The Difficulty Swallowing Pain Intensity Difference (PID) was calculated as the difference between the pain intensity (DSS range: 0mm=not difficult, 100mm=very difficult) at the time and at baseline.
Time frame: 7 to 24 hours Post-First Dose
Sum of Sore Throat Pain Intensity Difference (SPID2) as Measured by Difficulty Swallowing Scale (DSS) at 2 Hours Post-First Dose
SPID2 was calculated as the AUC of the Pain Intensity Difference (PID) scores. The Difficulty Swallowing PID was calculated as the difference between the pain intensity (DSS scale: 0mm=not difficult, 100mm=very difficult) at 2 hours post dose and at baseline.
Time frame: Over 2 hour Period Post-First Dose
Sum of Difficulty Swallowing Difference as Measured by Difficulty Swallowing Scale (DSS) Within 6 Hours Post-First Dose
The sum of pain intensity differences (SPID) was calculated as the AUC of the Pain Intensity Difference (PID) scores. The Difficulty Swallowing PID was calculated as the difference between the pain intensity (DSS range: 0mm=not difficult, 100mm=very difficult) at the time and at baseline.
Time frame: Within 6 hours Post-First Dose
Sum of Difficulty Swallowing Difference as Measured by Difficulty Swallowing Scale (DSS) From 7 to 24 Hours Post-First Dose
The sum of pain intensity differences (SPID) was calculated as the AUC of the Pain Intensity Difference (PID) scores. The Difficulty Swallowing PID was calculated as the difference between the pain intensity (DSS range: 0mm=not difficult, 100mm=very difficult) at the time and at baseline.
Time frame: 7 to 24 hours Post-First Dose
Difficulty Swallowing Scale (DSS) Difference at Least 50% Gone at 6 Hours Post-First Dose
Number of Subjects with \>= 50% Pain Intensity Difference (PID) on the DSS. The Difficulty Swallowing PID was calculated as the difference between the pain intensity (DSS scale: 0mm=not difficult, 100mm=very difficult) at 6 hours and at baseline.
Time frame: At 6 hours
Difficulty Swallowing Scale (DSS) Difference at Least 50% Gone at 12 Hours Post-First Dose
Number of Subjects with \>= 50% Pain Intensity Difference (PID) on the DSS. The Difficulty Swallowing PID was calculated as the difference between the pain intensity (DSS scale: 0mm=not difficult, 100mm=very difficult) at 12 hours and at baseline.
Time frame: At 12 Hours
Total Pain Relief (TOTPAR) at 2 and 6 Hours Post-First Dose
TOTPAR is time-interval-weighted sum of accumulated Sore Throat Relief Rating Scale (STRRS) scores (scale: 0 no relief to 6 complete relief).
Time frame: 2 and 6 hours Post-First Dose
Total Pain Relief (TOTPAR) at 12 and 24 Hours Post-First Dose
TOTPAR is time-interval-weighted sum of accumulated Sore Throat Relief Rating Scale (STRRS) scores (scale: 0 no relief to 6 complete relief).
Time frame: 12 and 24 hours Post-First Dose
Subjects With >= 50% Total Pain Relief (TOTPAR) at 6 Hours Post-First Dose
TOTPAR is time-interval-weighted sum of accumulated Sore Throat Relief Rating Scale (STRRS) scores (scale: 0 no relief to 6 complete relief). Maximum TOTPAR over 6 hours is 36. If the subject calculated TOTPAR is greater than or equal to 50% of the maximum TOTPAR then the subject is said to have achieved \>=50% TOTPAR.
Time frame: 6 hours Post-First Dose
Subjects With >= 50% Total Pain Relief (TOTPAR) at 12 Hours Post-First Dose
TOTPAR is time-interval-weighted sum of accumulated Sore Throat Relief Rating Scale (STRRS) scores (scale: 0 no relief to 6 complete relief). Maximum TOTPAR over 12 hours is 72. If the subject calculated TOTPAR is greater than or equal to 50% of the maximum TOTPAR then the subject is said to have achieved \>=50% TOTPAR.
Time frame: 12 hours Post-First Dose
Number Needed to Treat (NNT) to Achieve at Least 50% of Maximum Total Pain Relief (TOTPAR) at 6 Hours Post-First Dose
NNT is number of subjects needed to treat to have one extra subject report a 50% or better pain relief over 6 hours based on maximum possible pain relief on Sore Throat Relief Rating Scale. Maximum TOTPAR over 6 hours is 36. If the subject TOTPAR is greater than or equal to 50% of the maximum TOTPAR then the subject has achieved \>=50% TOTPAR.
Time frame: 6 hours Post-First Dose
Number Needed to Treat (NNT) to Achieve at Least 50% of Maximum Total Pain Relief (TOTPAR) at 12 Hours Post-First Dose
NNT is number of subjects needed to treat to have one subject report a 50% or better pain relief over 12 hours based on maximum possible pain relief on Sore Throat Relief Rating Scale. Maximum TOTPAR over 12 hours is 72. If the subject TOTPAR is greater than or equal to 50% of the maximum TOTPAR then the subject has achieved \>=50% TOTPAR.
Time frame: 12 hours Post-First Dose
Subjects With Sore Throat Pain at Least 35% Gone and at Least 50% Gone at 2 and 6 Hours Post-First Dose
\>= 35% and 50% Pain Intensity Difference (PID) on the Pain Intensity-Visual Analog Scale (PI-VAS) (scale: 0mm=no pain, 100mm=worst possible pain). The PID was calculated as the difference between the pain intensity at the time and at baseline.
Time frame: 2 and 6 hours Post-First Dose
Subjects With Sore Throat Pain at Least 35% Gone and at Least 50% Gone at 12 Hours Post-First Dose
\>= 35% and 50% Pain Intensity Difference (PID) on the Pain Intensity-Visual Analog Scale (PI-VAS) (scale: 0mm=no pain, 100mm=worst possible pain). The PID was calculated as the difference between the pain intensity at 12 hours and at baseline.
Time frame: 12 hours Post-First Dose
Subjects Who Achieved Their Own Level of 'Meaningful Relief' and 'Much Improvement' at 2 and 6 Hours Post-First Dose
Symptom relief measured as self-directed endpoints defined by each individual at end of study using Sore Throat Relief Rating Scale (STRRS); STRRS score ranges from 0=no relief to 6=complete relief. If subject scored same or greater in their STRRS during the study then they achieved their 'Meaningful Relief' or 'Much Improvement'.
Time frame: 2 and 6 hours Post-First Dose
Subjects Who Achieved Their Own Level of 'Meaningful Relief' and 'Much Improvement' at 12 Hours Post-First Dose
Symptom relief measured as self-directed endpoints defined by each individual at end of study using Sore Throat Relief Rating Scale (STRRS); STRRS score ranges from 0=no relief to 6=complete relief. If subject scored same or greater in their STRRS during the study then they achieved their 'Meaningful Relief' or 'Much Improvement'.
Time frame: 12 hours Post-First Dose
Subjects Who Achieved Their Own Level of 'Meaningful Relief' Within 6 Hours Who Had Perceptible Relief Onset Time Within 1 Hour
At end of study subjects defined meaningful pain relief by completing Meaningful Relief Scale. Meaningful relief was achieved if Sore Throat Relief Rating Scale (STRRS) score (range: 0=no relief to 6=complete relief) at end of the study was the same or higher than individually defined relief score during the study. Perceptible relief is STRRS \>0.
Time frame: Within 6 hours Post-First Dose
Subjects Who Achieved Their Own Level of 'Meaningful Relief' Within 6 Hours Who Still Had Perceptible Relief at 12 and 24 Hours Post-First Dose
At end of study subjects defined meaningful pain relief by completing the Meaningful Relief Scale. Meaningful relief was achieved if Sore Throat Relief Rating Scale (STRRS)(range: 0=no relief to 6=complete relief) score at end of the study was the same or higher than individually defined relief score during the study. Perceptible relief is STRRS \>0
Time frame: 12 and 24 hours Post-First Dose
Median Onset Time of First Perceptible Relief in Subjects Who Achieved Their Own Level of 'Meaningful Relief' Within 6 Hours Post-First Dose
Perceptible Relief is score \>0 on STRRS. Individual level of meaningful relief had to be reached within 6 hours. Meaningful Relief was achieved if Sore Throat Relief Rating Scale (STRRS)(range: 0=no relief to 6=complete relief)score at the end of the study was the same or higher than individually defined meaningful relief score during the study.
Time frame: 24 Hours
Median Offset Time of No Perceptible Relief in Subjects Who Achieved Their Own Level of 'Meaningful Relief' Within 6 Hours Post-First Dose
Offset time is time of first no perceptible relief (STRRS score=0) with meaningful relief (score\>0) at earlier time. STRRS score ranges from 0=no relief to 6=complete relief.
Time frame: 24 Hours
Treatment Failures on STRRS Questionnaire
Subjects were considered treatment failures if all of the STRRS scores were less than each individual's 'meaningful relief' scores. STRRS score ranges from 0=no relief to 6=complete relief.
Time frame: 24 hours Post-First Dose
Subjects Taking Rescue Medication
Subjects were allowed to use rescue medication at any time during the trial, but were discouraged from taking rescue medication within 2 hours of administration of the first dose of study drug.
Time frame: Within 24 hours Post-First Dose
Treatment Satisfaction Questionnaire for Medication (TSQM vII)
11 questions scored on factors: effectiveness, side effects, convenience, overall satisfaction. TSQM vII scores range 0 to 100, with higher scores indicating a higher level of global satisfaction with treatment.
Time frame: 24 hours or immediately prior to taking rescue medication
First Perceptible Relief
Subjects having First Perceptible Relief at each time point. Perceptible relief is score \>0 on Sore Throat Relief Rating Scale(STRRS)(range: 0=no relief to 6=complete relief).
Time frame: up to 24 hours
No Perceptible Relief
Subjects having No Perceptible Relief at each time point. No Perceptible relief is score = 0 on Sore Throat Relief Rating Scale (STRRS)(range: 0=no relief to 6=complete relief).
Time frame: up to 24 hours
1 center in the United States.
| Milestone | Celecoxib 50mg/50mg | Celecoxib 100mg/Placebo | Celecoxib 100mg/50mg | Placebo |
|---|---|---|---|---|
| Started | 90 | 45 | 45 | 89 |
| Completed | 90 | 45 | 44 | 89 |
| Not completed | 0 | 0 | 1 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 1 | 0 |
Based on the Pain Intensity scores measured on a Visual Analogue Scale (PI-VAS: 0mm=no pain,100mm=worst possible pain), assessed by the subjects, the SPID2 is the area under the curve (AUC) over the 2-hour period post-first dose of the Pain Intensity Difference (PID) scores using the trapezoidal rule.
| units on a scale * hours | Celecoxib 100mg (Pooled) | Placebo |
|---|---|---|
| Sum of Sore Throat Pain Intensity Difference (SPID2) on Swallowing at 2 Hours Post-First Dose | 21.0 ± 2.20 | 9.4 ± 2.21 |
Pain intensity (PI) on Swallowing as Measured by PI-VAS scale: 0mm=no pain, 100mm=worst possible pain. Sore throat PID score was obtained by subtracting the PI at each time point from the Baseline PI score. Increase in scores indicated a lessening of subjects' pain compared to baseline scores; higher scores indicated a greater reduction in pain.
| units on a scale | Celecoxib 50mg/50mg | Celecoxib 100mg (Pooled) | Placebo |
|---|---|---|---|
| 15 min | 1.62 ± 0.64 | 1.92 ± 0.64 | 0.40 ± 0.64 |
| 30 min | 4.70 ± 0.90 | 4.93 ± 0.90 | 2.14 ± 0.91 |
| 45 min | 9.57 ± 1.22 | 7.05 ± 1.23 | 3.85 ± 1.24 |
| 60 min | 12.18 ± 1.47 | 11.43 ± 1.47 | 5.34 ± 1.48 |
| 75 min | 17.24 ± 1.62 | 13.24 ± 1.62 | 6.60 ± 1.64 |
| 90 min | 22.39 ± 1.88 | 17.00 ± 1.88 | 6.75 ± 1.90 |
| 1.75 hours | 24.68 ± 1.99 | 18.80 ± 1.99 | 7.41 ± 2.01 |
| 2 hours | 26.63 ± 2.19 | 21.51 ± 2.19 | 8.06 ± 2.21 |
| 3 hours | 27.90 ± 2.29 | 22.21 ± 2.29 | 9.06 ± 2.31 |
| 4 hours | 25.52 ± 2.31 | 23.15 ± 2.31 | 10.35 ± 2.33 |
| 5 hours | 24.12 ± 2.26 | 23.56 ± 2.26 | 10.47 ± 2.28 |
| 6 hours | 21.42 ± 2.24 | 20.59 ± 2.24 | 9.04 ± 2.26 |
Pain intensity (PI) on Swallowing as Measured by PI-VAS scale: 0mm=no pain, 100mm=worst possible pain. PID score was obtained by subtracting the PI at each time point from the Baseline PI score. An increase in scores indicated a lessening of subjects' pain as compared to Baseline scores, thus, higher scores indicated a greater reduction in pain.
| units on a scale | Celecoxib 50mg/50mg | Celecoxib 100mg/Placebo | Celecoxib 100mg/50mg | Placebo |
|---|---|---|---|---|
| 7 hours | 20.82 ± 2.30 | 22.01 ± 3.26 | 18.34 ± 3.25 | 9.32 ± 2.33 |
| 8 hours | 20.39 ± 2.29 | 20.81 ± 3.24 | 19.93 ± 3.23 | 8.12 ± 2.31 |
| 9 hours | 21.39 ± 2.36 | 19.18 ± 3.35 | 18.87 ± 3.33 | 9.92 ± 2.38 |
| 10 hours | 21.26 ± 2.40 | 18.02 ± 3.40 | 18.06 ± 3.39 | 9.56 ± 2.42 |
| 11 hours | 19.65 ± 2.40 | 17.43 ± 3.40 | 18.99 ± 3.39 | 9.29 ± 2.43 |
| 12 hours | 19.01 ± 2.50 | 15.01 ± 3.54 | 20.22 ± 3.52 | 8.60 ± 2.52 |
| 24 hours | 18.43 ± 2.58 | 16.50 ± 3.66 | 19.44 ± 3.65 | 12.81 ± 2.61 |
The sum of pain intensity differences (SPID) was calculated as the AUC of the Pain Intensity Difference (PID) scores. The PID \[based on PI-VAS scale: 0mm=no pain, 100mm=worst possible pain\] was calculated as the difference between the pain intensity at the time and at baseline.
| units on a scale * hours | Celecoxib 50mg/50mg | Celecoxib 100mg (Pooled) | Placebo |
|---|---|---|---|
| 15 min | 0.2 ± 0.1 | 0.2 ± 0.1 | 0.1 ± 0.1 |
| 30 min | 1.0 ± 0.2 | 1.1 ± 0.2 | 0.4 ± 0.2 |
| 45 min | 2.8 ± 0.4 | 2.6 ± 0.4 | 1.1 ± 0.5 |
| 60 min | 5.5 ± 0.7 | 4.9 ± 0.7 | 2.3 ± 0.7 |
| 75 min | 9.2 ± 1.0 | 8.0 ± 1.0 | 3.8 ± 1.0 |
| 90 min | 14.1 ± 1.4 | 11.8 ± 1.4 | 5.4 ± 1.4 |
| 1.75 hours | 20.0 ± 1.8 | 16.2 ± 1.8 | 7.2 ± 1.8 |
| 2 hours | 26.4 ± 2.3 | 21.3 ± 2.3 | 9.1 ± 2.3 |
| 3 hours | 53.7 ± 4.3 | 43.1 ± 4.3 | 17.7 ± 4.4 |
| 4 hours | 80.4 ± 6.5 | 65.8 ± 6.5 | 27.4 ± 6.5 |
| 5 hours | 105.2 ± 8.5 | 89.2 ± 8.5 | 37.8 ± 8.6 |
| 6 hours | 128.0 ± 10.5 | 111.2 ± 10.5 | 47.6 ± 10.6 |
The sum of pain intensity differences (SPID) was calculated as the AUC of the Pain Intensity Difference (PID) scores. The PID \[based on PI-VAS scale: 0mm=no pain, 100mm=worst possible pain\] was calculated as the difference between the pain intensity at the time and at baseline.
| units on a scale * hours | Celecoxib 50mg/50mg | Celecoxib 100 mg / Placebo | Celecoxib 100mg / 50mg | Placebo |
|---|---|---|---|---|
| 7 hours | 149.2 ± 12.4 | 151.8 ± 17.5 | 111.6 ± 17.5 | 56.6 ± 12.5 |
| 8 hours | 169.8 ± 14.3 | 173.2 ± 20.3 | 130.8 ± 20.2 | 65.4 ± 14.5 |
| 9 hours | 190.7 ± 16.3 | 193.2 ± 23.1 | 150.2 ± 23.0 | 74.4 ± 16.5 |
| 10 hours | 212.0 ± 18.2 | 211.8 ± 25.9 | 168.6 ± 25.8 | 84.1 ± 18.4 |
| 11 hours | 232.4 ± 20.2 | 229.5 ± 28.7 | 187.2 ± 28.6 | 93.5 ± 20.5 |
| 12 hours | 251.8 ± 22.3 | 245.7 ± 31.6 | 206.8 ± 31.5 | 102.5 ± 22.5 |
| 24 hours | 476.4 ± 48.7 | 434.8 ± 69.0 | 444.7 ± 68.8 | 231.0 ± 49.2 |
STRRS score (scale: 0 no relief to 6 complete relief); a higher pain score indicated a greater reduction in pain.
| scores on a scale | Celecoxib 50mg/50mg | Celecoxib 100 mg (Pooled) | Placebo |
|---|---|---|---|
| 15 min | 0.12 ± 0.04 | 0.09 ± 0.04 | 0.16 ± 0.04 |
| 30 min | 0.41 ± 0.07 | 0.34 ± 0.07 | 0.34 ± 0.07 |
| 45 min | 0.74 ± 0.09 | 0.69 ± 0.09 | 0.52 ± 0.09 |
| 60 min | 1.22 ± 0.12 | 1.01 ± 0.12 | 0.64 ± 0.12 |
| 75 min | 1.58 ± 0.13 | 1.27 ± 0.13 | 0.79 ± 0.14 |
| 90 min | 1.88 ± 0.15 | 1.61 ± 0.15 | 0.88 ± 0.15 |
| 1.75 hours | 2.10 ± 0.16 | 1.74 ± 0.16 | 0.93 ± 0.16 |
| 2 hours | 2.22 ± 0.17 | 1.93 ± 0.17 | 0.92 ± 0.17 |
| 3 hours | 2.13 ± 0.17 | 1.92 ± 0.17 | 0.92 ± 0.17 |
| 4 hours | 2.08 ± 0.17 | 1.96 ± 0.17 | 1.10 ± 0.17 |
| 5 hours | 2.00 ± 0.17 | 1.97 ± 0.17 | 1.07 ± 0.17 |
| 6 hours | 1.81 ± 0.17 | 1.86 ± 0.17 | 0.96 ± 0.17 |
STRRS score (scale: 0 no relief to 6 complete relief); a higher score indicated a greater reduction in pain.
| scores on a scale | Celecoxib 50mg/50mg | Celecoxib 100 mg / Placebo | Celecoxib 100mg / 50mg | Placebo |
|---|---|---|---|---|
| 7 hours | 1.71 ± 0.17 | 2.00 ± 0.24 | 1.67 ± 0.24 | 0.93 ± 0.17 |
| 8 hours | 1.68 ± 0.17 | 1.80 ± 0.24 | 1.71 ± 0.24 | 0.97 ± 0.17 |
| 9 hours | 1.69 ± 0.17 | 1.76 ± 0.25 | 1.56 ± 0.25 | 1.08 ± 0.17 |
| 10 hours | 1.74 ± 0.17 | 1.67 ± 0.25 | 1.51 ± 0.25 | 1.08 ± 0.18 |
| 11 hours | 1.67 ± 0.18 | 1.58 ± 0.25 | 1.60 ± 0.25 | 1.10 ± 0.18 |
| 12 hours | 1.56 ± 0.18 | 1.42 ± 0.25 | 1.53 ± 0.25 | 1.07 ± 0.18 |
| 24 hours | 1.69 ± 0.19 | 1.62 ± 0.27 | 1.60 ± 0.27 | 1.31 ± 0.19 |
Subjects Achieving at Least 'Moderate Relief' as Measured by STRRS (range: 0=no relief to 6=complete relief); Moderate relief is defined as STRRS = 3).
| subjects | Celecoxib 50mg/50mg | Celecoxib 100 mg (Pooled) | Placebo |
|---|---|---|---|
| Sore Throat Relief Rating Scale (STRRS) - 'Moderate Relief' at 6 Hours Post-First Dose | 28 | 31 | 13 |
Subjects Achieving at Least 'Moderate Relief' as Measured by STRRS (range: 0=no relief to 6=complete relief); Moderate relief is defined as STRRS = 3).
| subjects | Celecoxib 50mg/50mg | Celecoxib 100 mg / Placebo | Celecoxib 100mg / 50mg | Placebo |
|---|---|---|---|---|
| Sore Throat Relief Rating Scale (STRRS) - 'Moderate Relief' at 12 Hours Post-First Dose | 21 | 13 | 12 | 14 |
Defined as time (measured by stopwatch) when subject began to feel any pain relieving effect from the drug
| minutes | Celecoxib 50mg/50mg | Celecoxib 100 mg (Pooled) | Placebo |
|---|---|---|---|
| Time to Perceptible Pain Relief | 49 (45 to 61) | 61 (46 to 75) | 97 (62 to 120) |
The time (measured by stopwatch) when the subject felt their pain relief was meaningful to them was not estimable thus the number of subjects experiencing meaningful pain relief within 2 hours of first dose is reported
| subjects | Celecoxib 50mg/50mg | Celecoxib 100 mg (Pooled) | Placebo |
|---|---|---|---|
| Time to Meaningful Pain Relief | 36 (NA to NA) | 33 (NA to NA) | 15 (NA to NA) |
Equal to time of perceptible pain relief when both perceptible pain relief and meaningful pain relief were experienced- the median time was not estimable thus the number of subjects with onset of analgesia within 2 hours of first dose is reported
| subjects | Celecoxib 50mg/50mg | Celecoxib 100 mg (Pooled) | Placebo |
|---|---|---|---|
| Time to Onset of Analgesia | 36 (NA to NA) | 34 (NA to NA) | 15 (NA to NA) |
Subject assessment of overall impression of study drug on 4 point scale from 1 (poor) to 4 (excellent)
| subjects | Celecoxib 50mg/50mg | Celecoxib 100 mg (Pooled) | Placebo |
|---|---|---|---|
| Excellent (4) | 5 | 4 | 2 |
| Good (3) | 24 | 25 | 5 |
| Fair (2) | 25 | 27 | 22 |
| Poor (1) | 35 | 33 | 60 |
Subject assessment of overall impression of study drug on 4 point scale from 1 (poor) to 4 (excellent)
| subjects | Celecoxib 50mg/50mg | Celecoxib 100 mg / Placebo | Celecoxib 100mg / 50mg | Placebo |
|---|---|---|---|---|
| Excellent (4) - 12 hours | 8 | 5 | 0 | 1 |
| Good (3) - 12 hours | 23 | 10 | 13 | 10 |
| Fair (2) - 12 hours | 21 | 11 | 11 | 18 |
| Poor (1) - 12 hours | 37 | 18 | 20 | 56 |
| Excellent (4) - 24 hours | 7 | 4 | 2 | 2 |
| Good (3) - 24 hours | 20 | 13 | 9 | 13 |
| Fair (2) - 24 hours | 25 | 7 | 15 | 15 |
| Poor (1) - 24 hours | 37 | 21 | 18 | 57 |
The Pain Intensity Difference (PID) based on TSS (scale: 0=not sore to 10=very sore) was calculated as the difference between the pain intensity at the time and at baseline.
| scores on a scale | Celecoxib 50mg/50mg | Celecoxib 100mg (Pooled) | Placebo |
|---|---|---|---|
| 15 min | 0.06 ± 0.04 | 0.06 ± 0.04 | 0.06 ± 0.04 |
| 30 min | 0.39 ± 0.08 | 0.36 ± 0.08 | 0.29 ± 0.08 |
| 45 min | 0.74 ± 0.10 | 0.66 ± 0.10 | 0.43 ± 0.10 |
| 60 min | 1.17 ± 0.13 | 0.97 ± 0.13 | 0.60 ± 0.13 |
| 75 min | 1.62 ± 0.15 | 1.29 ± 0.15 | 0.75 ± 0.15 |
| 90 min | 1.97 ± 0.17 | 1.64 ± 0.17 | 0.76 ± 0.17 |
| 1.75 hours | 2.24 ± 0.18 | 1.86 ± 0.18 | 0.79 ± 0.19 |
| 2 hours | 2.39 ± 0.19 | 2.03 ± 0.19 | 0.78 ± 0.19 |
| 3 hours | 2.43 ± 0.20 | 2.09 ± 0.20 | 0.85 ± 0.21 |
| 4 hours | 2.14 ± 0.21 | 2.12 ± 0.21 | 1.01 ± 0.21 |
| 5 hours | 2.03 ± 0.20 | 2.06 ± 0.21 | 1.04 ± 0.21 |
| 6 hours | 1.83 ± 0.20 | 1.90 ± 0.20 | 0.90 ± 0.21 |
The Pain Intensity Difference (PID) based on TSS (scale: 0=not sore to 10=very sore) was calculated as the difference between the pain intensity at the time and at baseline.
| scores on a scale | Celecoxib 50mg/50mg | Celecoxib 100mg/Placebo | Celecoxib 100mg/50mg | Placebo |
|---|---|---|---|---|
| 7 hours | 1.65 ± 0.21 | 1.95 ± 0.30 | 1.68 ± 0.29 | 0.78 ± 0.21 |
| 8 hours | 1.67 ± 0.21 | 1.65 ± 0.30 | 1.70 ± 0.30 | 0.76 ± 0.22 |
| 9 hours | 1.76 ± 0.22 | 1.60 ± 0.32 | 1.65 ± 0.32 | 0.90 ± 0.23 |
| 10 hours | 1.80 ± 0.23 | 1.58 ± 0.33 | 1.63 ± 0.32 | 0.87 ± 0.23 |
| 11 hours | 1.76 ± 0.23 | 1.53 ± 0.32 | 1.76 ± 0.32 | 0.87 ± 0.23 |
| 12 hours | 1.53 ± 0.23 | 1.37 ± 0.33 | 1.80 ± 0.33 | 0.82 ± 0.24 |
| 24 hours | 1.62 ± 0.25 | 1.46 ± 0.36 | 1.78 ± 0.35 | 1.17 ± 0.25 |
SPID2 was calculated as the AUC of the Pain Intensity Difference (PID) scores. The Sore Throat PID was calculated as the difference between the pain intensity (TSS scale: 0=not sore to 10=very sore) at 2 hours post dose and at baseline.
| units on a scale * hours | Celecoxib 50mg/50mg | Celecoxib 100mg (Pooled) | Placebo |
|---|---|---|---|
| Sore Throat Pain Intensity Difference (SPID2) as Measured by Throat Soreness Scale (TSS) at 2 Hours Post-First Dose | 2.4 ± 0.21 | 2.0 ± 0.21 | 1.0 ± 0.21 |
The sum of sore throat pain intensity differences (SPID) was calculated as the AUC of the Pain Intensity Difference (PID) scores. The Sore Throat PID was calculated as the difference between the pain intensity (TSS range: 0=not sore to 10=very sore) at the time and at baseline.
| units on a scale * hours | Celecoxib 50mg/50mg | Celecoxib 100mg (Pooled) | Placebo |
|---|---|---|---|
| 15 min | 0.01 ± 0.01 | 0.01 ± 0.01 | 0.01 ± 0.01 |
| 30 min | 0.07 ± 0.02 | 0.06 ± 0.02 | 0.05 ± 0.02 |
| 45 min | 0.21 ± 0.03 | 0.19 ± 0.03 | 0.14 ± 0.04 |
| 60 min | 0.45 ± 0.06 | 0.39 ± 0.06 | 0.27 ± 0.06 |
| 75 min | 0.80 ± 0.09 | 0.67 ± 0.09 | 0.44 ± 0.09 |
| 90 min | 1.24 ± 0.13 | 1.04 ± 0.13 | 0.63 ± 0.13 |
| 1.75 hours | 1.77 ± 0.16 | 1.48 ± 0.16 | 0.82 ± 0.17 |
| 2 hours | 2.35 ± 0.21 | 1.96 ± 0.21 | 1.02 ± 0.21 |
| 3 hours | 4.76 ± 0.39 | 4.02 ± 0.39 | 1.83 ± 0.39 |
| 4 hours | 7.05 ± 0.58 | 6.12 ± 0.58 | 2.76 ± 0.59 |
| 5 hours | 9.13 ± 0.76 | 8.21 ± 0.77 | 3.79 ± 0.77 |
| 6 hours | 11.07 ± 0.94 | 10.20 ± 0.94 | 4.75 ± 0.95 |
The sum of sore throat pain intensity differences (SPID) was calculated as the AUC of the Pain Intensity Difference (PID) scores. The Sore Throat PID was calculated as the difference between the pain intensity (TSS range: 0=not sore to 10=very sore) at the time and at baseline.
| units on a scale * hours | Celecoxib 50mg/50mg | Celecoxib 100mg/Placebo | Celecoxib 100mg/50mg | Placebo |
|---|---|---|---|---|
| 7 hours | 12.8 ± 1.1 | 14.2 ± 1.6 | 9.9 ± 1.6 | 5.6 ± 1.1 |
| 8 hours | 14.5 ± 1.3 | 16.0 ± 1.8 | 11.6 ± 1.8 | 6.3 ± 1.3 |
| 9 hours | 16.2 ± 1.5 | 17.7 ± 2.1 | 13.3 ± 2.1 | 7.2 ± 1.5 |
| 10 hours | 18.0 ± 1.7 | 19.3 ± 2.4 | 14.9 ± 2.3 | 8.1 ± 1.7 |
| 11 hours | 19.7 ± 1.8 | 20.8 ± 2.6 | 16.6 ± 2.6 | 8.9 ± 1.9 |
| 12 hours | 21.4 ± 2.0 | 22.3 ± 2.9 | 18.4 ± 2.9 | 9.8 ± 2.1 |
| 24 hours | 40.3 ± 4.5 | 39.2 ± 6.4 | 39.8 ± 6.4 | 21.7 ± 4.6 |
The Difficulty Swallowing Pain Intensity Difference (PID) was calculated as the difference between the pain intensity (DSS range: 0mm=not difficult, 100mm=very difficult) at the time and at baseline.
| units on a scale | Celecoxib 50mg/50mg | Celecoxib 100mg (Pooled) | Placebo |
|---|---|---|---|
| 15 min | 1.69 ± 0.89 | 1.16 ± 0.89 | 0.81 ± 0.89 |
| 30 min | 4.85 ± 1.21 | 3.14 ± 1.21 | 1.11 ± 1.21 |
| 45 min | 6.99 ± 1.43 | 5.75 ± 1.43 | 2.85 ± 1.44 |
| 60 min | 11.21 ± 1.65 | 8.02 ± 1.65 | 3.53 ± 1.66 |
| 75 min | 14.31 ± 1.84 | 10.47 ± 1.84 | 3.95 ± 1.85 |
| 90 min | 17.40 ± 1.99 | 12.21 ± 1.99 | 3.97 ± 2.00 |
| 1.75 hours | 20.52 ± 2.11 | 15.15 ± 2.11 | 4.45 ± 2.12 |
| 2 hours | 21.76 ± 2.25 | 16.50 ± 2.25 | 4.99 ± 2.26 |
| 3 hours | 22.20 ± 2.17 | 18.39 ± 2.17 | 4.20 ± 2.18 |
| 4 hours | 20.53 ± 2.33 | 18.27 ± 2.33 | 7.28 ± 2.34 |
| 5 hours | 18.40 ± 2.31 | 18.11 ± 2.31 | 6.02 ± 2.32 |
| 6 hours | 16.62 ± 2.27 | 16.43 ± 2.27 | 5.70 ± 2.29 |
The Difficulty Swallowing Pain Intensity Difference (PID) was calculated as the difference between the pain intensity (DSS range: 0mm=not difficult, 100mm=very difficult) at the time and at baseline.
| units on a scale | Celecoxib 50mg/50mg | Celecoxib 100mg/Placebo | Celecoxib 100mg/50mg | Placebo |
|---|---|---|---|---|
| 7 hours | 16.91 ± 2.35 | 18.11 ± 3.32 | 11.38 ± 3.32 | 4.86 ± 2.36 |
| 8 hours | 16.53 ± 2.38 | 17.29 ± 3.37 | 13.40 ± 3.37 | 4.88 ± 2.39 |
| 9 hours | 16.59 ± 2.35 | 15.10 ± 3.32 | 12.68 ± 3.32 | 5.46 ± 2.36 |
| 10 hours | 16.61 ± 2.39 | 14.32 ± 3.38 | 11.68 ± 3.38 | 5.85 ± 2.41 |
| 11 hours | 15.01 ± 2.45 | 12.99 ± 3.46 | 13.13 ± 3.46 | 5.22 ± 2.46 |
| 12 hours | 15.40 ± 2.51 | 11.44 ± 3.55 | 13.41 ± 3.55 | 5.30 ± 2.53 |
| 24 hours | 14.25 ± 2.70 | 13.67 ± 3.83 | 13.24 ± 3.82 | 8.79 ± 2.72 |
SPID2 was calculated as the AUC of the Pain Intensity Difference (PID) scores. The Difficulty Swallowing PID was calculated as the difference between the pain intensity (DSS scale: 0mm=not difficult, 100mm=very difficult) at 2 hours post dose and at baseline.
| units on a scale * hours | Celecoxib 50mg/50mg | Celecoxib 100mg (Pooled) | Placebo |
|---|---|---|---|
| Sum of Sore Throat Pain Intensity Difference (SPID2) as Measured by Difficulty Swallowing Scale (DSS) at 2 Hours Post-First Dose | 22.0 ± 2.73 | 16.0 ± 2.73 | 5.8 ± 2.75 |
The sum of pain intensity differences (SPID) was calculated as the AUC of the Pain Intensity Difference (PID) scores. The Difficulty Swallowing PID was calculated as the difference between the pain intensity (DSS range: 0mm=not difficult, 100mm=very difficult) at the time and at baseline.
| units on a scale * hours | Celecoxib 50mg/50mg | Celecoxib 100mg (Pooled) | Placebo |
|---|---|---|---|
| 15 min | 0.2 ± 0.1 | 0.1 ± 0.1 | 0.1 ± 0.1 |
| 30 min | 1.0 ± 0.3 | 0.7 ± 0.3 | 0.3 ± 0.3 |
| 45 min | 2.5 ± 0.6 | 1.8 ± 0.6 | 0.8 ± 0.6 |
| 60 min | 4.8 ± 1.0 | 3.5 ± 1.0 | 1.6 ± 1.0 |
| 75 min | 8.0 ± 1.4 | 5.8 ± 1.4 | 2.6 ± 1.4 |
| 90 min | 11.9 ± 1.8 | 8.7 ± 1.8 | 3.6 ± 1.8 |
| 1.75 hours | 16.7 ± 2.2 | 12.1 ± 2.2 | 4.6 ± 2.3 |
| 2 hours | 22.0 ± 2.7 | 16.0 ± 2.7 | 5.8 ± 2.8 |
| 3 hours | 43.9 ± 4.8 | 33.5 ± 4.8 | 10.4 ± 4.8 |
| 4 hours | 65.3 ± 6.8 | 51.8 ± 6.8 | 16.1 ± 6.9 |
| 5 hours | 84.8 ± 9.0 | 70.0 ± 9.0 | 22.8 ± 9.0 |
| 6 hours | 102.3 ± 11.0 | 87.3 ± 11.0 | 28.6 ± 11.1 |
The sum of pain intensity differences (SPID) was calculated as the AUC of the Pain Intensity Difference (PID) scores. The Difficulty Swallowing PID was calculated as the difference between the pain intensity (DSS range: 0mm=not difficult, 100mm=very difficult) at the time and at baseline.
| units on a scale * hours | Celecoxib 50mg/50mg | Celecoxib 100mg/Placebo | Celecoxib 100mg/50mg | Placebo |
|---|---|---|---|---|
| 7 hours | 119.1 ± 13.0 | 133.6 ± 18.3 | 72.2 ± 18.3 | 33.9 ± 13.0 |
| 8 hours | 135.8 ± 15.0 | 151.3 ± 21.3 | 84.5 ± 21.3 | 38.8 ± 15.1 |
| 9 hours | 152.3 ± 17.1 | 167.5 ± 24.2 | 97.6 ± 24.2 | 43.9 ± 17.2 |
| 10 hours | 168.9 ± 19.1 | 182.2 ± 27.0 | 109.8 ± 27.0 | 49.6 ± 19.2 |
| 11 hours | 184.7 ± 21.1 | 195.8 ± 29.9 | 122.2 ± 29.9 | 55.1 ± 21.3 |
| 12 hours | 200.0 ± 23.2 | 208.0 ± 32.8 | 135.4 ± 32.8 | 60.4 ± 23.4 |
| 24 hours | 377.9 ± 50.4 | 358.7 ± 71.3 | 295.3 ± 71.3 | 144.9 ± 50.7 |
Number of Subjects with \>= 50% Pain Intensity Difference (PID) on the DSS. The Difficulty Swallowing PID was calculated as the difference between the pain intensity (DSS scale: 0mm=not difficult, 100mm=very difficult) at 6 hours and at baseline.
| subjects | Celecoxib 50mg/50mg | Celecoxib 100mg (Pooled) | Placebo |
|---|---|---|---|
| Difficulty Swallowing Scale (DSS) Difference at Least 50% Gone at 6 Hours Post-First Dose | 22 | 24 | 14 |
Number of Subjects with \>= 50% Pain Intensity Difference (PID) on the DSS. The Difficulty Swallowing PID was calculated as the difference between the pain intensity (DSS scale: 0mm=not difficult, 100mm=very difficult) at 12 hours and at baseline.
| subjects | Celecoxib 50mg/50mg | Celecoxib 100mg/Placebo | Celecoxib 100mg/50mg | Placebo |
|---|---|---|---|---|
| Difficulty Swallowing Scale (DSS) Difference at Least 50% Gone at 12 Hours Post-First Dose | 24 | 12 | 10 | 12 |
TOTPAR is time-interval-weighted sum of accumulated Sore Throat Relief Rating Scale (STRRS) scores (scale: 0 no relief to 6 complete relief).
| scores on a scale | Celecoxib 50mg/50mg | Celecoxib 100mg (Pooled) | Placebo |
|---|---|---|---|
| 2 hours | 2.6 ± 0.2 | 2.2 ± 0.2 | 1.3 ± 0.2 |
| 6 hours | 10.6 ± 0.8 | 9.9 ± 0.8 | 5.3 ± 0.8 |
TOTPAR is time-interval-weighted sum of accumulated Sore Throat Relief Rating Scale (STRRS) scores (scale: 0 no relief to 6 complete relief).
| scores on a scale | Celecoxib 50mg/50mg | Celecoxib 100mg /Placebo | Celecoxib 100mg/50mg | Placebo |
|---|---|---|---|---|
| 12 hours | 20.6 ± 1.7 | 22.0 ± 2.4 | 17.5 ± 2.4 | 11.6 ± 1.7 |
| 24 hours | 40.9 ± 3.6 | 41.5 ± 5.1 | 36.7 ± 5.1 | 27.3 ± 3.7 |
TOTPAR is time-interval-weighted sum of accumulated Sore Throat Relief Rating Scale (STRRS) scores (scale: 0 no relief to 6 complete relief). Maximum TOTPAR over 6 hours is 36. If the subject calculated TOTPAR is greater than or equal to 50% of the maximum TOTPAR then the subject is said to have achieved \>=50% TOTPAR.
| subjects | Celecoxib 50mg/50mg | Celecoxib 100mg (Pooled) | Placebo |
|---|---|---|---|
| Subjects With >= 50% Total Pain Relief (TOTPAR) at 6 Hours Post-First Dose | 18 | 19 | 7 |
TOTPAR is time-interval-weighted sum of accumulated Sore Throat Relief Rating Scale (STRRS) scores (scale: 0 no relief to 6 complete relief). Maximum TOTPAR over 12 hours is 72. If the subject calculated TOTPAR is greater than or equal to 50% of the maximum TOTPAR then the subject is said to have achieved \>=50% TOTPAR.
| subjects | Celecoxib 50mg/50mg | Celecoxib 100mg/Placebo | Celecoxib 100mg/50mg | Placebo |
|---|---|---|---|---|
| Subjects With >= 50% Total Pain Relief (TOTPAR) at 12 Hours Post-First Dose | 18 | 12 | 8 | 6 |
NNT is number of subjects needed to treat to have one extra subject report a 50% or better pain relief over 6 hours based on maximum possible pain relief on Sore Throat Relief Rating Scale. Maximum TOTPAR over 6 hours is 36. If the subject TOTPAR is greater than or equal to 50% of the maximum TOTPAR then the subject has achieved \>=50% TOTPAR.
| subjects | Celecoxib 50mg/50mg | Celecoxib 100mg (Pooled) | Placebo |
|---|---|---|---|
| Number Needed to Treat (NNT) to Achieve at Least 50% of Maximum Total Pain Relief (TOTPAR) at 6 Hours Post-First Dose | 18 | 19 | 7 |
NNT is number of subjects needed to treat to have one subject report a 50% or better pain relief over 12 hours based on maximum possible pain relief on Sore Throat Relief Rating Scale. Maximum TOTPAR over 12 hours is 72. If the subject TOTPAR is greater than or equal to 50% of the maximum TOTPAR then the subject has achieved \>=50% TOTPAR.
| subjects | Celecoxib 50mg/50mg | Celecoxib 100mg/Placebo | Celecoxib 100mg/50mg | Placebo |
|---|---|---|---|---|
| Number Needed to Treat (NNT) to Achieve at Least 50% of Maximum Total Pain Relief (TOTPAR) at 12 Hours Post-First Dose | 18 | 12 | 8 | 6 |
\>= 35% and 50% Pain Intensity Difference (PID) on the Pain Intensity-Visual Analog Scale (PI-VAS) (scale: 0mm=no pain, 100mm=worst possible pain). The PID was calculated as the difference between the pain intensity at the time and at baseline.
| subjects | Celecoxib 50mg/50mg | Celecoxib 100mg (Pooled) | Placebo |
|---|---|---|---|
| 2 hours >=35% gone | 39 | 32 | 15 |
| 6 hours >=35% gone | 31 | 29 | 12 |
| 2 hours >=50% gone | 28 | 24 | 8 |
| 6 hours >=50% gone | 23 | 22 | 9 |
\>= 35% and 50% Pain Intensity Difference (PID) on the Pain Intensity-Visual Analog Scale (PI-VAS) (scale: 0mm=no pain, 100mm=worst possible pain). The PID was calculated as the difference between the pain intensity at 12 hours and at baseline.
| subjects | Celecoxib 50mg/50mg | Celecoxib 100mg/Placebo | Celecoxib 100mg/50mg | Placebo |
|---|---|---|---|---|
| 12 hours >=35% gone | 30 | 13 | 12 | 13 |
| 12 hours >=50% gone | 22 | 12 | 10 | 9 |
Symptom relief measured as self-directed endpoints defined by each individual at end of study using Sore Throat Relief Rating Scale (STRRS); STRRS score ranges from 0=no relief to 6=complete relief. If subject scored same or greater in their STRRS during the study then they achieved their 'Meaningful Relief' or 'Much Improvement'.
| subjects | Celecoxib 50mg/50mg | Celecoxib 100mg (Pooled) | Placebo |
|---|---|---|---|
| meaningful relief - 2 hours- achieved | 31 | 26 | 12 |
| meaningful relief- 2 hours- not achieved | 59 | 63 | 77 |
| meaningful relief - 6 hours- achieved | 40 | 38 | 17 |
| meaningful relief- 6 hours- not achieved | 50 | 51 | 72 |
| much improvement - 2 hours- achieved | 22 | 22 | 10 |
| much improvement - 2 hours- not achieved | 68 | 67 | 79 |
| much improvement - 6 hours- achieved | 33 | 31 | 12 |
| much improvement - 6 hours- not achieved | 57 | 58 | 77 |
Symptom relief measured as self-directed endpoints defined by each individual at end of study using Sore Throat Relief Rating Scale (STRRS); STRRS score ranges from 0=no relief to 6=complete relief. If subject scored same or greater in their STRRS during the study then they achieved their 'Meaningful Relief' or 'Much Improvement'.
| subjects | Celecoxib 50mg/50mg | Celecoxib 100mg /Placebo | Celecoxib 100mg/50mg | Placebo |
|---|---|---|---|---|
| Meaningful Relief - achieved | 44 | 26 | 20 | 20 |
| Meaningful Relief - not achieved | 46 | 19 | 24 | 69 |
| Much Improvement - achieved | 38 | 22 | 12 | 16 |
| Much Improvement - not achieved | 52 | 23 | 32 | 73 |
At end of study subjects defined meaningful pain relief by completing Meaningful Relief Scale. Meaningful relief was achieved if Sore Throat Relief Rating Scale (STRRS) score (range: 0=no relief to 6=complete relief) at end of the study was the same or higher than individually defined relief score during the study. Perceptible relief is STRRS \>0.
| subjects | Celecoxib 50mg/50mg | Celecoxib 100mg (Pooled) | Placebo |
|---|---|---|---|
| Achieved | 31 | 27 | 12 |
| Not achieved | 59 | 62 | 77 |
At end of study subjects defined meaningful pain relief by completing the Meaningful Relief Scale. Meaningful relief was achieved if Sore Throat Relief Rating Scale (STRRS)(range: 0=no relief to 6=complete relief) score at end of the study was the same or higher than individually defined relief score during the study. Perceptible relief is STRRS \>0
| subjects | Celecoxib 50mg/50mg | Celecoxib 100mg/Placebo | Celecoxib 100mg/50mg | Placebo |
|---|---|---|---|---|
| at 12 hours - Achieved | 32 | 16 | 12 | 11 |
| at 12 hours - Not Achieved | 58 | 29 | 32 | 78 |
| at 24 hours - Achieved | 28 | 16 | 9 | 11 |
| at 24 hours - Not Achieved | 62 | 29 | 35 | 78 |
Perceptible Relief is score \>0 on STRRS. Individual level of meaningful relief had to be reached within 6 hours. Meaningful Relief was achieved if Sore Throat Relief Rating Scale (STRRS)(range: 0=no relief to 6=complete relief)score at the end of the study was the same or higher than individually defined meaningful relief score during the study.
| hours | Celecoxib 50mg/50mg | Celecoxib 100mg (Pooled) | Placebo |
|---|---|---|---|
| Median Onset Time of First Perceptible Relief in Subjects Who Achieved Their Own Level of 'Meaningful Relief' Within 6 Hours Post-First Dose | 0.75 (0.25 to 3.00) | 0.63 (0.25 to 1.50) | 0.50 (0.25 to 6.00) |
Offset time is time of first no perceptible relief (STRRS score=0) with meaningful relief (score\>0) at earlier time. STRRS score ranges from 0=no relief to 6=complete relief.
| hours | Celecoxib 50mg/50mg | Celecoxib 100mg/Placebo | Celecoxib 100mg/50mg | Placebo |
|---|---|---|---|---|
| Median Offset Time of No Perceptible Relief in Subjects Who Achieved Their Own Level of 'Meaningful Relief' Within 6 Hours Post-First Dose | 8.00 (3.00 to 24.00) | 8.00 (1.25 to 9.00) | 8.00 (3.00 to 24.00) | 10.00 (2.00 to 12.00) |
Subjects were considered treatment failures if all of the STRRS scores were less than each individual's 'meaningful relief' scores. STRRS score ranges from 0=no relief to 6=complete relief.
| subjects | Celecoxib 50mg/50mg | Celecoxib 100mg/Placebo | Celecoxib 100mg/50mg | Placebo |
|---|---|---|---|---|
| Not treatment failures | 46 | 27 | 20 | 23 |
| Treatment failures | 44 | 18 | 24 | 66 |
Subjects were allowed to use rescue medication at any time during the trial, but were discouraged from taking rescue medication within 2 hours of administration of the first dose of study drug.
| subjects | Celecoxib 50mg/50mg | Celecoxib 100mg /Placebo | Celecoxib 100mg/50mg | Placebo |
|---|---|---|---|---|
| Subjects Taking Rescue Medication | 22 | 15 | 13 | 39 |
11 questions scored on factors: effectiveness, side effects, convenience, overall satisfaction. TSQM vII scores range 0 to 100, with higher scores indicating a higher level of global satisfaction with treatment.
| scores on a scale | Celecoxib 50mg/50mg | Celecoxib 100mg /Placebo | Celecoxib 100mg/50mg | Placebo |
|---|---|---|---|---|
| Effectiveness | 41.5 ± 26.6 | 40.6 ± 28.7 | 34.3 ± 26.2 | 26.1 ± 25.4 |
| Side Effects | 96.3 ± 12.0 | 96.7 ± 11.6 | 97.9 ± 9.7 | 98.6 ± 8.2 |
| Convenience | 77.2 ± 15.1 | 73.0 ± 17.4 | 69.3 ± 16.8 | 71.3 ± 14.6 |
| Global Satisfaction | 49.1 ± 28.0 | 47.8 ± 33.4 | 42.2 ± 30.6 | 36.0 ± 27.3 |
Subjects having First Perceptible Relief at each time point. Perceptible relief is score \>0 on Sore Throat Relief Rating Scale(STRRS)(range: 0=no relief to 6=complete relief).
| subjects | Celecoxib 50mg/50mg | Celecoxib 100mg/Placebo | Celecoxib 100mg/50mg | Placebo |
|---|---|---|---|---|
| 1 hour - Onset subjects in hour | 68 | 29 | 22 | 40 |
| 1 hour - No onset subjects in hour | 22 | 16 | 23 | 49 |
| 2 hour - Onset subjects in hour | 13 | 10 | 9 | 11 |
| 2 hour-No onset subjects in hour | 9 | 6 | 14 | 38 |
| 3 hour - Onset subjects in hour | 1 | 2 | 0 | 2 |
| 3 hour-No onset subjects in hour | 8 | 4 | 14 | 36 |
| 4 hour - Onset subjects in hour | 0 | 0 | 2 | 4 |
| 4 hour- No onset subjects in hour | 8 | 4 | 12 | 32 |
| 5 hour - Onset subjects in hour | 0 | 0 | 1 | 4 |
| 5 hour-No onset subjects in hour | 8 | 4 | 11 | 28 |
| 6 hour - Onset subjects in hour | 0 | 1 | 3 | 1 |
| 6 hour-No onset subjects in hour | 8 | 3 | 8 | 27 |
| 7 hour - Onset subjects in hour | 0 | 0 | 1 | 1 |
| 7 hour-No onset subjects in hour | 8 | 3 | 7 | 26 |
| 8 hour - Onset subjects in hour | 0 | 0 | 1 | 2 |
| 8 hour-No onset subjects in hour | 8 | 3 | 6 | 24 |
| 9 hour - Onset subjects in hour | 2 | 0 | 0 | 2 |
| 9 hour-No onset subjects in hour | 6 | 3 | 6 | 22 |
| 10 hour - Onset subjects in hour | 0 | 0 | 0 | 0 |
| 10 hour-No onset subjects in hour | 6 | 3 | 6 | 22 |
| 11 hour - Onset subjects in hour | 0 | 0 | 0 | 1 |
| 11 hour-No onset subjects in hour ( | 6 | 3 | 6 | 21 |
| 12 hour - Onset subjects in hour | 0 | 0 | 0 | 1 |
| 12 hour-No onset subjects in hour | 6 | 3 | 6 | 20 |
| 24 hour - Onset subjects in hour | 1 | 0 | 0 | 2 |
| 24 hour-No onset subjects in hour | 5 | 3 | 6 | 18 |
Subjects having No Perceptible Relief at each time point. No Perceptible relief is score = 0 on Sore Throat Relief Rating Scale (STRRS)(range: 0=no relief to 6=complete relief).
| subjects | Celecoxib 50mg/50mg | Celecoxib 100mg/Placebo | Celecoxib 100mg/50mg | Placebo |
|---|---|---|---|---|
| 1 hour - Offset subjects in hour | 0 | 0 | 0 | 0 |
| 1 hour-No offset subjects in hour | 90 | 45 | 45 | 89 |
| 2 hour- Offset subjects in hour | 0 | 1 | 0 | 1 |
| 2 hour-No offset subjects in hr | 90 | 44 | 45 | 88 |
| 3 hour- Offset subjects in hour | 1 | 0 | 1 | 0 |
| 3 hour-No offset subjects in hr | 89 | 44 | 44 | 88 |
| 4 hour- Offset subjects in hour | 0 | 0 | 0 | 0 |
| 4 hour-No offset subjects in hr | 89 | 44 | 44 | 88 |
| 5 hour- Offset subjects in hour | 1 | 0 | 0 | 0 |
| 5 hour-No offset subjects in hr | 88 | 44 | 44 | 88 |
| 6 hour- Offset subjects in hour | 0 | 0 | 0 | 1 |
| 6 hour-No offset subjects in hr | 88 | 44 | 44 | 87 |
| 7 hour- Offset subjects in hour | 4 | 2 | 2 | 1 |
| 7 hour-No offset subjects in hr | 84 | 42 | 42 | 86 |
| 8 hour- Offset subjects in hour | 1 | 2 | 0 | 0 |
| 8 hour-No offset subjects in hr | 83 | 40 | 42 | 86 |
| 9 hour- Offset subjects in hour | 1 | 3 | 1 | 0 |
| 9 hour-No offset subjects in hr | 82 | 37 | 41 | 86 |
| 10 hour-Offset subjects in hour | 2 | 0 | 0 | 3 |
| 10 hour-No offset subjects in hr | 80 | 37 | 41 | 83 |
| 11 hour-Offset subjects in hour | 1 | 0 | 0 | 0 |
| 11 hour-No offset subjects in hr | 79 | 37 | 41 | 83 |
| 12 hour-Offset subjects in hour | 1 | 0 | 0 | 2 |
| 12 hour-No offset subjects in hr | 78 | 37 | 41 | 81 |
| 24 hour-Offset subjects in hour (N=78,37, 41, 81) | 3 | 0 | 3 | 0 |
| 24 hour-No offset subjects in hr (N=78,37,41, 81) | 75 | 37 | 38 | 81 |
Collected over Baseline (Day 1) up to 28 days after last dose of study drug ( up to a maximum of 30 days). Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Celecoxib 50mg/50mg | 0/90 (0%) | 0/90 (0%) | 8/90 (8.9%) |
| Celecoxib 100mg/Placebo | 0/45 (0%) | 0/45 (0%) | 5/45 (11.1%) |
| Celecoxib 100mg/50mg | 0/45 (0%) | 0/45 (0%) | 5/45 (11.1%) |
| Placebo | 0/89 (0%) | 0/89 (0%) | 6/89 (6.7%) |
| Event | Celecoxib 50mg/50mg | Celecoxib 100mg/Placebo | Celecoxib 100mg/50mg | Placebo |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 3/90 | 2/45 | 0/45 | 1/89 |
| DyspepsiaGastrointestinal disorders | 0/90 | 0/45 | 0/45 | 2/89 |
| ConjunctivitisEye disorders | 1/90 | 0/45 | 1/45 | 1/89 |
| FatigueGeneral disorders | 1/90 | 1/45 | 0/45 | 0/89 |
| Otitis mediaInfections and infestations | 0/90 | 0/45 | 1/45 | 1/89 |
| DizzinessNervous system disorders | 2/90 | 0/45 | 0/45 | 1/89 |
| HeadacheNervous system disorders | 2/90 | 0/45 | 0/45 | 0/89 |
| WheezingRespiratory, thoracic and mediastinal disorders | 0/90 | 0/45 | 1/45 | 1/89 |
| Rash generalizedSkin and subcutaneous tissue disorders | 0/90 | 1/45 | 1/45 | 0/89 |
| Abdominal distensionGastrointestinal disorders | 0/90 | 1/45 | 0/45 | 0/89 |
| Age, Continuous(years) | Celecoxib 50mg/50mg | Celecoxib 100mg/Placebo | Celecoxib 100mg/50mg | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 19.5 ± 1.3 | 19.6 ± 1.4 | 19.9 ± 2.3 | 19.3 ± 1.4 | 19.5 ± 1.5 |
| Sex: Female, Male(Participants) | Celecoxib 50mg/50mg | Celecoxib 100mg/Placebo | Celecoxib 100mg/50mg | Placebo | Total |
|---|---|---|---|---|---|
| Female | 55 | 25 | 15 | 49 | 144 |
| Male | 35 | 20 | 30 | 40 | 125 |
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Dec 2006 to primary completion in Nov 2007, 11 months.
Results were first posted in Mar 2009, 1 year 3 months after primary completion.
Of 13 phase 3 interventional studies under Pharyngitis, half reached primary completion within 3 months of starting (the median); a quarter within 2 and three quarters within 6. This study's 11 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Celecoxib
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →